FORTUNE — Jeff Kindler has a new job, nearly two years after being ousted as CEO of drug giant Pfizer (PFE). Well, at least a part-time one.
Kindler has agreed to join venture capital firm Lux Capital, where he will “help identify new healthcare investment opportunities and work with Lux portfolio companies.”
Lux co-founder Peter Hébert says that Kindler already has helped source a few potential investments, and is expected to eventually represent the firm on certain boards of directors. More important, Lux is hoping that Kindler will be able to recruit portfolio company executives and identify acquirers for its existing healthcare investments.
“Jeff has an incredible corporate Rolodex that can help bring credible CEOs to some of our companies,” Hébert explains, adding that he was originally introduced to Kindler via Lux venture partner Dick Foster (co-founder of McKinsey & Co.’s tech practice).
Kindler was not available for comment. In addition to his role at Lux, he serves on several corporate and nonprofit boards, plus is a director of private equity firm Starboard Capital Partners.
Lux Capital currently is investing out of its third fund ($200m target, not sure how much got raised), with a diverse focus on energy, technology and healthcare startups. Current healthcare portfolio companies include Cerulean (nanotech-based drug efficacy/safety improvements), Genocea Biosciences (vaccine development) and Keros (molecular imaging agents).
Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com